DAM
DMAAR

DLD Asset Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

DLD Asset Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9K Buy
126,594
+25,000
+25% +$2.58K ﹤0.01% 418
2026
Q1 		$6.14K Hold
101,594
– – ﹤0.01% 353
2025
Q4 		$19K Buy
+101,594
New +$19.7K ﹤0.01% 351

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

DLD Asset Management's DMAAR Position: Q2 2026 in Review

DLD Asset Management increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 25% in Q2 2026, buying an estimated $2.58K and bringing the position to 126,594 shares worth $13.9K. The position accounts for ﹤0.01% of the portfolio, ranked #418.

DLD Asset Management first reported a position in DMAAR in Q4 2025 and has held it in 3 quarters since. The position peaked at $19K in Q4 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • DLD Asset Management held 126,594 shares of Drugs Made In America Acquisition Corp Rights worth $13.9K as of Q2 2026.
  • DLD Asset Management bought 25,000 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $2.58K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of DLD Asset Management's portfolio in Q2 2026, its #418 holding.
  • DLD Asset Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q4 2025 and has held it in 3 quarters since.
  • DLD Asset Management's Drugs Made In America Acquisition Corp Rights position peaked at $19K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on DLD Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.